我要投票 康恩贝在牛初乳行业中的票数:276
· 外 推 电 报 ·
2025-06-04 08:13:42 星期三

【康恩贝是哪个国家的品牌?】

康恩贝是什么牌子?「康恩贝」是 浙江康恩贝制药股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人胡季强在1993-01-09期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力康恩贝品牌出海!将品牌入驻外推网,定制康恩贝品牌推广信息,可以显著提高康恩贝产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~


浙江康恩贝制药股份有限公司是康恩贝集团有限公司的控股子公司,是一家集药材种植及药品研发、生产、销售为一体的医药上市企业。公司的前身为创建于1969年的“兰溪云山制药厂”,1990年更名为“浙江康恩贝制药公司”;1992年6月5日,经浙江省股份制试点工作协调小组批准,浙江康恩贝制药公司改组为“浙江康恩贝股份有限公司”;1999年10月,公司正式更名为“浙江康恩贝制药股份有限公司”。

公司注册地为兰溪,管理总部设在浙江省杭州市,公司在杭州、兰溪、金华,以及江西、云南、内蒙古、四川等地拥有先进规范的药品生产基地,并在兰溪建有国内最大的现代植物药制造基地——康恩贝植物药产业园。公司旗下拥有浙江康恩贝中药有限公司、浙江金华康恩贝生物制药有限公司、云南希陶绿色药业股份有限公司、杭州康恩贝制药有限公司、江西天施康中药股份有限公司、浙江康恩贝药品研究开发有限公司、浙江康恩贝医药销售有限公司、上海康恩贝医药有限公司、云南康恩贝植物药有限公司、内蒙古康恩贝药业有限公司等多个颇具规模和实力的全资及控股子公司。

公司为国家火炬计划重点高新技术企业、国家创新型企业、国家知识产权试点企业、国家中药二十强企业、科技部中药现代化科技产业基地先进单位、浙江省“五个一批”重点骨干企业、浙江省重点企业研究院、浙江省专利示范企业、浙江省创新型示范企业,建有国家认定企业技术中心、国家博士后科研工作站、院士工作站、浙江省中药制药技术重点实验室、省级研发中心和技术中心,是浙江省首批重点企业技术创新团队。

公司拥有一支由博士、硕士和高、中级职称的技术人员组成的实力雄厚、专注于现代植物药和特色化学药研发的团队,与国内外知名科研机构、大专院校建立了长期的战略合作伙伴和战略联盟,已建立新药研发的多个技术平台,通过聘请行业权威人士组成研发专家委员会,在心脑血管系统用药、泌尿系统用药、抗糖尿病用药、呼吸道系统用药、消化系统用药和抗感染药等药物的研发,以及植物提取分离和结构改造、新型药物释放系统应用等诸多方面,以现代植物药、特色化学药发展为主线,研发具有自主知识产权的新药,在药材种植、原料药和植物提取、新药研发、制剂生产、市场营销等各环节,已建立起规范高效的产业体系。

公司历来十分重视产品品牌和企业品牌的培育和保护,在泌尿系统及心脑血管系统等多个领域建立了消费者熟知与认可的品牌,如今,公司已成为浙江省拥有著名商标和名牌产品最多的企业之一。其中,“康恩贝”、“前列康”、“珍视明”被认定为中国驰名商标,“阿乐欣”、“金康”、“金奥康”、“希陶”、“天保康”、“天狮”等均在各自领域拥有较高的品牌知名度,在同类竞争产品中已树立起了较突出的品牌优势。

展望未来,公司将继续秉承“集天下才智,创宏伟事业,为人类健康、献至诚至爱”的企业宗旨,恪守“诚实守信、依法经营,质量第一、顾客至上,安全第一、友好环境,关爱员工、奉献社会”的四大天条,倡导并培育公司和谐与激情并进的文化氛围,努力发挥公司整体实力和品牌优势,一如既往地致力于现代植物药领域的创新发展,将康恩贝打造成为中国最具品牌价值的医药企业和世界植物药领军企业!


英文翻译:Zhejiang Kangenbei Pharmaceutical Co., Ltd. is a holding subsidiary of Kangenbei Group Co., Ltd. It is a pharmaceutical listed enterprise integrating the cultivation of medicinal materials, drug research and development, production and sales. The predecessor of the company is "Lanxi Yunshan pharmaceutical factory" founded in 1969, renamed as "Zhejiang Kangenbei pharmaceutical company" in 1990; on June 5, 1992, Zhejiang Kangenbei pharmaceutical company was reorganized as "Zhejiang Kangenbei Co., Ltd." with the approval of Zhejiang joint stock pilot work coordination group; in October 1999, the company was officially renamed as "Zhejiang Kangenbei Pharmaceutical Co., Ltd." " The company is registered in Lanxi, with its management headquarters in Hangzhou, Zhejiang Province. The company has advanced and standardized drug production bases in Hangzhou, Lanxi, Jinhua, Jiangxi, Yunnan, Inner Mongolia, Sichuan and other places. In Lanxi, it has the largest modern plant drug manufacturing base in China, Kangenbei plant drug Industrial Park. The company has Zhejiang kangenbe traditional Chinese Medicine Co., Ltd., Zhejiang Jinhua kangenbe Biological Pharmaceutical Co., Ltd., Yunnan Xitao green Pharmaceutical Co., Ltd., Hangzhou kangenbe Pharmaceutical Co., Ltd., Jiangxi tianshikang traditional Chinese Medicine Co., Ltd., Zhejiang kangenbe pharmaceutical research and Development Co., Ltd., Zhejiang kangenbe Pharmaceutical Sales Co., Ltd., and Shanghai kangenbe Pharmaceutical Co., Ltd , Yunnan Kangenbei Plant Medicine Co., Ltd., Inner Mongolia Kangenbei Pharmaceutical Co., Ltd. and many other wholly-owned and holding subsidiaries with considerable scale and strength. The company is a key high-tech enterprise of the national torch plan, a national innovative enterprise, a national intellectual property pilot enterprise, a top 20 enterprise of the national traditional Chinese medicine, an advanced unit of the modern science and technology industrial base of traditional Chinese medicine of the Ministry of science and technology, a "five batch" key backbone enterprise of Zhejiang Province, a Research Institute of key enterprises of Zhejiang Province, a patent demonstration enterprise of Zhejiang Province, and an innovative demonstration enterprise of Zhejiang Province The state recognized enterprise technology center, National Postdoctoral research workstation, academician workstation, Zhejiang Key Laboratory of traditional Chinese medicine pharmaceutical technology, provincial R & D center and technology center are the first batch of key enterprise technology innovation teams in Zhejiang Province. The company has a strong team composed of doctors, masters and technicians with senior and intermediate professional titles, focusing on the research and development of modern plant medicine and characteristic chemical medicine. It has established long-term strategic partners and strategic alliances with well-known scientific research institutions and colleges at home and abroad. It has established multiple technical platforms for new drug research and development, and hired industry authorities to form research and development experts The committee, in the research and development of cardiovascular and cerebrovascular system drugs, urinary system drugs, antidiabetic drugs, respiratory system drugs, digestive system drugs and anti infective drugs, as well as plant extraction and separation, structural transformation, application of new drug delivery system, etc., takes the development of modern plant drugs and characteristic chemicals as the main line, and develops new drugs with independent intellectual property rights, A standardized and efficient industrial system has been established in various links such as the cultivation of medicinal materials, the extraction of raw materials and plants, the research and development of new drugs, the production of preparations, and the marketing. The company has always attached great importance to the cultivation and protection of product brands and enterprise brands. It has established brands well known and recognized by consumers in many fields such as urinary system, cardiovascular and cerebrovascular system. Now, the company has become one of the most famous brands and famous brand products in Zhejiang Province. Among them, "Kangenbei", "QianLieKang" and "Zhenshiming" are recognized as well-known trademarks in China, "alexin", "Jinkang", "jinaokang", "Xitao", "Tianbaokang" and "Tianshi" all have high brand awareness in their respective fields, and have established prominent brand advantages in similar competitive products. Looking forward to the future, the company will continue to adhere to the enterprise tenet of "gathering the wisdom of the world, creating a grand cause, serving the health of mankind, offering sincere love", adhere to the four tenets of "honest and trustworthy, operating according to law, quality first, customer first, safety first, friendly environment, caring for employees and contributing to the society", advocate and cultivate a harmonious and passionate cultural atmosphere of the company, and strive to play The company's overall strength and brand advantage, as always, is committed to the innovation and development of modern botanical medicine field, and will build Kangenbei into the most famous pharmaceutical enterprise in China and the world's leading enterprise in botanical medicine!

本文链接: https://www.waitui.com/brand/34532c964.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

摩根大通赋予Lake更大职责,Viswanathan离职

摩根大通任命Marianne Lake掌管战略性增长和快速扩张的海外消费者银行业务。Lake是未来可能接替首席执行官杰米·戴蒙的重要人选之一。备忘录显示,此次任命是在Sanoke Viswanathan离职之后作出。Viswanathan将出任数据公司FactSet的首席执行官。Viswanathan曾为摩根大通执行委员会成员,此前曾被视为戴蒙的另一位潜在接班人。(新浪财经)

14分钟前

多家公募自购新发浮动费率基金

正在发行中的新模式浮动费率基金依然备受市场瞩目,多家基金公司更是用真金白银表达对旗下产品的支持。6月3日,兴证全球基金发布公告,拟运用固有资金2000万元认购旗下兴证全球合熙混合型证券投资基金。公开信息显示,该基金为首批新模式浮动费率基金之一,将于6月4日起发行。为了实现与投资者利益的深度捆绑,发动自购的基金公司正在不断增加。(上证报)

14分钟前

医药主题基金否极泰来,机构顺势发力布局

沉寂已久的创新药板块否极泰来,带动医药主题基金业绩飙涨,多只基金今年以来收益超过50%。医药板块赚钱效应显著,吸引机构布局,近期多只新基金密集成立,长线资金也纷纷入场,医药赛道投资热度陡升。在业内人士看来,创新药企积极出海,产业升级势不可挡,后市投资机会可期。Choice数据显示,截至5月30日,共有18只主动权益类基金今年以来收益超过50%,其中12只重仓创新药板块。(上证报)

14分钟前

新消费成市场讨论热词,公募机构持续加大投研力度

6月3日,多只新消费概念股继续上涨,部分个股连创新高。值得注意的是,今年以来,老铺黄金、泡泡玛特、蜜雪集团、会稽山等持续表现强势,新消费逐渐成为市场讨论的热词。遗憾的是,许多公募基金却在此前缺席新消费投资。近期调研了解到,对于新消费投资,一些基金经理从质疑到理解,再到加大投研力度,目前对相关个股的投研覆盖度已有大幅提升。与此同时,基金经理对新消费板块的后市也存在一定分歧。有观点认为,在积累了较大涨幅后,部分新消费标的估值可能过高,需要警惕调整风险;也有观点认为,在业绩超预期的支撑下,后市新消费标的空间仍值得期待。(中证报)

14分钟前

上市公司回购热度不减

Wind数据显示,5月以来,截至6月3日,A股共440家上市公司对外发布回购相关公告。5月单月,发布新一轮回购方案的有78家上市公司,数量仅次于4月份。同时,回购注销案例备受市场关注。回购增持贷款方面,Wind数据显示,自2024年10月以来,截至目前,A股共650家上市公司或重要股东获回购增持贷款,回购增持贷款总金额约为1370亿元。(中证报)

14分钟前

本页详细列出关于康恩贝的品牌信息,含品牌所属公司介绍,康恩贝所处行业的品牌地位及优势。
咨询